Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
Autolus Therapeutics (AUTL) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript [Seeking Alpha]
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data [Yahoo! Finance]
Autolus Therapeutics to Participate in Upcoming Investor Conferences